JP5462797B2 - 注射可能なメクリジン製剤および方法 - Google Patents

注射可能なメクリジン製剤および方法 Download PDF

Info

Publication number
JP5462797B2
JP5462797B2 JP2010532276A JP2010532276A JP5462797B2 JP 5462797 B2 JP5462797 B2 JP 5462797B2 JP 2010532276 A JP2010532276 A JP 2010532276A JP 2010532276 A JP2010532276 A JP 2010532276A JP 5462797 B2 JP5462797 B2 JP 5462797B2
Authority
JP
Japan
Prior art keywords
meclizine
cyclodextrin
pharmaceutically acceptable
chemically modified
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010532276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502169A5 (fr
JP2011502169A (ja
Inventor
ロング，ウォーカー・アンダーソン
マーフィー，エドウィン・カレン
Original Assignee
ジーンバイオロジー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーンバイオロジー，インコーポレイテッド filed Critical ジーンバイオロジー，インコーポレイテッド
Publication of JP2011502169A publication Critical patent/JP2011502169A/ja
Publication of JP2011502169A5 publication Critical patent/JP2011502169A5/ja
Application granted granted Critical
Publication of JP5462797B2 publication Critical patent/JP5462797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010532276A 2007-10-31 2008-10-31 注射可能なメクリジン製剤および方法 Active JP5462797B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/980,845 US8138192B2 (en) 2007-10-31 2007-10-31 Injectable meclizine formulations and methods
US11/980,845 2007-10-31
PCT/US2008/081973 WO2009059120A2 (fr) 2007-10-31 2008-10-31 Formulations injectables de méclizine et procédés afférents

Publications (3)

Publication Number Publication Date
JP2011502169A JP2011502169A (ja) 2011-01-20
JP2011502169A5 JP2011502169A5 (fr) 2012-02-02
JP5462797B2 true JP5462797B2 (ja) 2014-04-02

Family

ID=40583655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532276A Active JP5462797B2 (ja) 2007-10-31 2008-10-31 注射可能なメクリジン製剤および方法

Country Status (10)

Country Link
US (2) US8138192B2 (fr)
EP (1) EP2219606B1 (fr)
JP (1) JP5462797B2 (fr)
AU (1) AU2008318536B2 (fr)
CA (1) CA2704430C (fr)
ES (1) ES2657937T3 (fr)
NZ (1) NZ584942A (fr)
PT (1) PT2219606T (fr)
WO (1) WO2009059120A2 (fr)
ZA (1) ZA201003524B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150859A1 (fr) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Formulations aqueuses orales de méclizine comprenant un agent aromatisant
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2019178536A1 (fr) * 2018-03-16 2019-09-19 The Regents Of The University Of California Inhibiteurs de mtor et utilisations associées

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60204712A (ja) 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
US4729997A (en) 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2002032459A2 (fr) 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Procede permettant d'ameliorer l'efficacite des antibiotiques par complexion avec des cyclodextrines
US20060120967A1 (en) 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils

Also Published As

Publication number Publication date
CA2704430C (fr) 2016-04-05
WO2009059120A3 (fr) 2009-08-06
AU2008318536B2 (en) 2013-09-26
ZA201003524B (en) 2011-03-30
NZ584942A (en) 2012-09-28
EP2219606B1 (fr) 2017-12-27
US20120108608A1 (en) 2012-05-03
WO2009059120A2 (fr) 2009-05-07
PT2219606T (pt) 2018-02-02
CA2704430A1 (fr) 2009-05-07
ES2657937T3 (es) 2018-03-07
EP2219606A4 (fr) 2013-03-06
US8293749B2 (en) 2012-10-23
EP2219606A2 (fr) 2010-08-25
US20090111833A1 (en) 2009-04-30
JP2011502169A (ja) 2011-01-20
US8138192B2 (en) 2012-03-20
AU2008318536A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
EP2785352B1 (fr) Compositions pharmaceutiques injectables stables comprenant de la 2-hydroxypropyl-beta-cyclodextrine et de l'alfaxalone
KR101747476B1 (ko) 마취 제제
JP4334229B2 (ja) プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
EP3310331B1 (fr) Formulations pharmaceutiques injectables de léfamuline
JP5462797B2 (ja) 注射可能なメクリジン製剤および方法
EP3556349B1 (fr) Préparation liquide parentérale comprenant un composé carbamate
US20030027791A1 (en) Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
US20040072797A1 (en) Storage stable eplerenone formulation
JP4275394B2 (ja) 注射用シロスタゾール水性製剤
WO2024172852A1 (fr) Compositions pharmaceutiques stables d'édaravone

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140117

R150 Certificate of patent or registration of utility model

Ref document number: 5462797

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250